Last updated on June 2018

PRASTERONE (DHEA) FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) - (PLACEBO-CONTROLLED, DOUBLE-BLIND AND RANDOMIZED PHASE III STUDY OF 24-WEEK INTRAVAGINAL PRASTERONE) - PROTOCOL ERC-242


Brief description of study

Sexual Dysfunction

Detailed Study Description

The objective of this study is to confirm the efficacy of intravaginal DHEA (also named prasterone) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women. We will also evaluate the effects of study treatment on the number of satisfying (pleasing) sexual events (SSEs). This study will last 28 weeks and involve a minimum of 6 visits at the clinic and 1 follow-up phone call. Some questionnaires will also need to be filled out at home using an electronic tablet.

Compensation for study visits may be provided to qualified study participants.

Clinical Study Identifier: TX154512

Contact Investigators or Research Sites near you

Start Over

Mellissa Henry, R.N., M.S.N., N.P.

Pharmacology Research Institute, Los Alamitos
Los Alamitos, CA USA
  Connect »